Triple terapia en diabetes tipo 2: revisión sistemática de la evidencia disponible

Committee C.D.A.-C.P.G.E., 2008, Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada, Can J Diabetes., 3, 1 National Collaborating Centre for Chronic Conditions, 2008 Nathan, 2009, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy, Diabetologia., 52, 17, 10.1007/s00125-008-1157-y Work Group of Institute for Clinical Systems Improvement (ICSI)., 2009 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract., 15, 540, 10.4158/EP.15.6.540 Grupo de Trabajo de la Guía de Práctica Clínica sobre Diabetes tipo 2. Guía de práctica clínica sobre diabetes tipo 2. Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco, Guías de Práctica Clínica en el SNS: OSTEBA n.° 2006/08. 2008. Dailey, 2004, Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial, Am J Med., 116, 223, 10.1016/j.amjmed.2003.07.022 Charpentier, 2009, Earlier triple therapy with pioglitazone in patients with type 2 diabetes, Diabetes Obes Metab., 11, 844, 10.1111/j.1463-1326.2009.01055.x Dorkhan, 2006, Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes, J Intern Med., 260, 125, 10.1111/j.1365-2796.2006.01665.x Yale, 2001, The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter randomized, double-blind, placebo-controlled trial, Ann Intern Med., 134, 737, 10.7326/0003-4819-134-9_Part_1-200105010-00010 Ovalle, 1998, Triple oral antidiabetic therapy in type 2 diabetes mellitus, Endocr Pract., 4, 146, 10.4158/EP.4.3.146 Bell, 2002, Long-term efficacy of triple oral therapy for type 2 diabetes mellitus, Endocr Pract., 8, 271, 10.4158/EP.8.4.271 Kiayias, 2002, Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients, Diabetes Care., 25, 1251, 10.2337/diacare.25.7.1251 Byrne, 2003, Efficacy of triple combination oral hypoglycaemic therapy using rosiglitazone, metformin and sulphonylurea in lowering HbA1c, Practical Diabetes International., 20, 58, 10.1002/pdi.446 Roy, 2004, Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent, Diabetes Care., 27, 1741, 10.2337/diacare.27.7.1741 Roberts, 2005, Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther., 27, 1535, 10.1016/j.clinthera.2005.10.017 Strowig, 2004, Improved glycemic control without weight gain using triple therapy in type 2 diabetes, Diabetes Care., 27, 1577, 10.2337/diacare.27.7.1577 Rosenstock, 2006, Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients, Diabetes Care., 29, 554, 10.2337/diacare.29.03.06.dc05-0695 Bell, 2007, Triple oral therapy for type 2 diabetes, Diabetes Res Clin Pract., 78, 313, 10.1016/j.diabres.2007.01.003 Lam, 1998, Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study, Diabetes Care., 21, 1154, 10.2337/diacare.21.7.1154 Standl, 2001, Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics, Diabetes Res Clin Pract., 51, 205, 10.1016/S0168-8227(00)00231-X Hermansen, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Sitagliptin Study 035 Group, Diabetes Obes Metab., 9, 733, 10.1111/j.1463-1326.2007.00744.x Penfornis, 2008, Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies, Diabetes Metab., 34, 78, 10.1016/S1262-3636(08)73399-8 Halimi, 2008, DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?, Diabetes Metab., 34, 91, 10.1016/S1262-3636(08)73400-1 Zinman, 2009, LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Diabetes Care., 32, 1224, 10.2337/dc08-2124 Tran, 2006, Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes, Diabetes Care., 29, 1395, 10.2337/dc06-0494 Schwartz, 2003, Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis, Diabetes Care., 26, 2238, 10.2337/diacare.26.8.2238 Lingvay, 2007, Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted, J Investig Med., 55, 62, 10.2310/6650.2007.06036 Aljabri, 2004, Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial, Am J Med., 116, 230, 10.1016/j.amjmed.2003.07.023 Holman, 2007, 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes, N Engl J Med., 357, 1716, 10.1056/NEJMoa075392 Holman, 2009, Three-year efficacy of complex insulin regimens in type 2 diabetes, N Engl J Med., 361, 1736, 10.1056/NEJMoa0905479 Vinik, 2007, Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes, Diabetes Care., 30, 795, 10.2337/dc06-1712 Poulsen, 2003, The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients, Diabetes Care., 26, 3273, 10.2337/diacare.26.12.3273 Home, 2007, Double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes, Diabet Med., 24, 618, 10.1111/j.1464-5491.2007.02141.x Juurinen, 2009, Nateglinide combination therapy with basal insulin and metformin in patients with type 2 diabetes, Diabet Med., 26, 409, 10.1111/j.1464-5491.2009.02691.x Sharma, 2009, Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats, Eur J Pharm Sci., 38, 433, 10.1016/j.ejps.2009.09.004